Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Galapagos Hit By Atopic Dermatitis Drug Fail

End For IL-7C Inhibitor Partnered With MorphoSys And Novartis

Oct 29 2019

• By Kevin Grogan

Lizard — IGUANA study halted after futility analysis • Source: Shutterstock

Related Content

AbbVie’s Post-Humira Strategy Continues Taking Shape With Rinvoq Approval

Aug 16 2019

Novartis Pushes Dermatology Momentum By Licensing Atopic Dermatitis MAb

Jul 19 2018

$5bn Galapagos Deal Won’t Be Last For Gilead, Says O’Day

Jul 15 2019

Gilead Hopes Selectivity Will Ease Safety Labeling For Filgotinib

Oct 25 2019

Related Companies

Galapagos NV

MorphoSys AG

Novartis AG

Sanofi

Regeneron Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Pfizer Inc.

Eli Lilly and Company

AbbVie Inc.

Additional Topics

Clinical Trials Companies Research & Development Strategy Immune Disorders BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window